ADIM
EXAS

Alpha DNA Investment Management’s Exact Sciences EXAS Stock Holding History

Alpha DNA Investment Management’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,645
Closed -$566K – 215
2023
Q4 		$566K Sell
7,645
-804
-10% -$52.7K 0.22% 89
2023
Q3 		$576K Sell
8,449
-3,221
-28% -$273K 0.24% 96
2023
Q2 		$1.1M Sell
11,670
-3,672
-24% -$286K 0.37% 54
2023
Q1 		$1.04M Buy
+15,342
New +$986K 0.31% 105
2021
Q2 		– Sell
-9
Closed -$1K – 277
2021
Q1 		$1K Buy
+9
New +$1.23K ﹤0.01% 619

Other funds holding EXAS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Alpha DNA Investment Management's EXAS Position: Q1 2024 in Review

Alpha DNA Investment Management sold out of Exact Sciences (EXAS) in Q1 2024, closing a stake of 7,645 shares — an estimated $566K sold.

Alpha DNA Investment Management first reported a position in EXAS in Q1 2021 and held it in 5 quarters. The position peaked at $1.1M in Q2 2023. 627 funds tracked by Wall St. Rank hold EXAS as of Q1 2024.

  • Alpha DNA Investment Management reported no remaining Exact Sciences position as of Q1 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 7,645 Exact Sciences shares in Q1 2024, an estimated $566K.
  • Alpha DNA Investment Management first reported a position in Exact Sciences in Q1 2021 and held it in 5 quarters.
  • Alpha DNA Investment Management's Exact Sciences position peaked at $1.1M in Q2 2023.
  • 627 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2024.

Based on Alpha DNA Investment Management's 13F filing for Q1 2024, filed 15 May 2024.